Cucurbitacin A

Cucurbitacin A

SCHEMBL20121493

CC(=O)OC(C)(C)/C=C/C(=O)C(C)(O)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC=C4[C@@H](C[C@H](O)C(=O)C4(C)C)[C@]3(CO)C(=O)C[C@]12C

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGAL P20701 3/20 0.82
NPC1 O15118 2/20 0.82
RAB9A P51151 2/20 0.82
IGF2BP1 Q9NZI8 2/20 0.82
SMN1; SMN2 Q16637 2/20 0.82
HIF1A Q16665 2/20 0.82
LMNA P02545 1/20 0.82
MAPT P10636 1/20 0.82
STAT3 P40763 1/20 0.82
HTT P42858 1/20 0.82
ATM Q13315 1/20 0.82
KMT2A Q03164 1/20 0.75
ACHE P22303 2/20 0.56
PAX8 Q06710 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CYP3A4 P08684 1/20 0.49
TYR P14679 1/20 0.36
PTPN1 P18031 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cucurbitacin A SCHEMBL22877913 1.00 ITGAL (0.82) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Cucurbitacin A SCHEMBL22877821 1.00 ITGAL (0.82) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Cucurbitacin A SCHEMBL10307352 1.00 ITGAL (0.82) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL20121442 0.90 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL18177462 0.90 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL17531553 0.90 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL22433345 0.90 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL13668120 0.90 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL19186443 0.90 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Cucurbitacin B SCHEMBL29602393 0.90 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661266-B1 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ANJI PHARMA (US) LLC (US) 2020-09-16 EP disclosed
US-10610500-B2 Chemosensory receptor ligand-based therapies ANJI PHARMA (US) LLC (US) 2020-04-07 US disclosed
US-20190038576-A1 Chemosensory Receptor Ligand-Based Therapies ANJI PHARMACEUTICALS INC. 2019-02-07 US disclosed
US-9962344-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2018-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10610500-B2 Chemosensory receptor ligand-based therapies TAS1R2, TAS2R1, GPR119 ITGAL 2328/4885NPC1 923/4885RAB9A 3767/4885
US-20190038576-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 ITGAL 2328/4885NPC1 923/4885RAB9A 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.